ANKRD30BP2: A Potential Drug Target and Biomarker (G149992)

Target Name: ANKRD30BP2

NCBI ID: G149992

ANKRD30BP2

ANKRD30BP2: A Potential Drug Target and Biomarker

Ankyrin A30 (ANKRD30BP2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the heat shock protein (HSP) gene family, which plays a critical role in the stress response of cells. ANKRD30BP2 has been shown to be highly expressed in various tissues and conditions, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). Its potential as a drug target makes it an attractive subject of research, and its role as a biomarker has implications for the development of new diagnostic tests.

The HSP gene family is a group of non-coding RNAs that play a crucial role in the regulation of protein synthesis and quality control. These genes are highly conserved across various species, and they have been implicated in a wide range of cellular processes, including stress response, DNA replication, and cell survival. The HSP70 family of proteins is one of the most well-studied, and it is known to play a central role in the regulation of protein synthesis and stability.

ANKRD30BP2 is a member of the HSP70 family of proteins and is expressed in various tissues and conditions. It has been shown to play a critical role in the regulation of heat shock protein (HSP) gene expression in response to various stress conditions, including stress, starvation, and exercise. ANKRD30BP2 has been shown to regulate the expression of HSP70 proteins through a variety of mechanisms, including direct binding to HSP70 protein and indirect effects on the stability of HSP70 protein.

In addition to its role in the regulation of HSP70 protein expression, ANKRD30BP2 has also been shown to play a critical role in the regulation of cellular processes that are relevant to its function as a drug target. For example, ANKRD30BP2 has been shown to be involved in the regulation of cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cell cycle progression, and it is involved in the regulation of the G1/S transition that occurs during the cell cycle.

The potential drug target status of ANKRD30BP2 is supported by its expression in various tissues and conditions that are known to be sensitive to drugs that target the HSP70 protein. For example, ANKRD30BP2 is expressed in various tissues that are known to be sensitive to chemotherapy, such as breast cancer and ovarian cancer. It is also expressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells.

The potential biomarker status of ANKRD30BP2 is supported by its expression in various tissues and conditions that are known to be sensitive to drugs that affect the HSP70 protein. For example, ANKRD30BP2 is expressed in various tissues that are known to be sensitive to drugs that affect the HSP70 protein, such as cancer cells and heart cells. It is also expressed in conditions that are characterized by the loss of cellular organelles, such as the lungs and the liver.

In conclusion, ANKRD30BP2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its expression in various tissues and conditions that are sensitive to drugs that affect the HSP70 protein supports its potential as a drug target. Further research is needed to fully understand the role of ANKRD30BP2 as a drug target and biomarker, and to develop new diagnostic tests that can be used to detect its expression in various tissues

Protein Name: Ankyrin Repeat Domain 30B Pseudogene 2

The "ANKRD30BP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD30BP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets